source
- AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly dealMore details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition. In an SEC filing on Thursday morning, AtaiBeckley disclosed some of the play-by-play from itsEndpoints · 5h ago↗ source
- Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stockAlnylam’s second-quarter earnings report Thursday did little to assuage investor concerns in what has already been a difficult year for the company. The drugmaker lowered its full-year sales projec…Endpoints · 7h ago↗ source
- STAT+: Rising oil prices can boost the cost of some medicines. One expert says it’s time to lower reliance on fossil fuelsUnitaid found the rising price of oil could boost the cost of a widely used HIV medicine it reviewed in a detailed analysis.